<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726452</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE (ICORG) 10-14</org_study_id>
    <nct_id>NCT01726452</nct_id>
  </id_info>
  <brief_title>NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)</brief_title>
  <official_title>Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southampton Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region H Rigshospitalet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional, Universitaire de Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate one, two and three year survival of patients treated with resection plus
      neoadjuvant and adjuvant chemotherapy versus resection plus neoadjuvant chemo radiotherapy.

      Secondary Objective(s):

      To evaluate the effect of both neoadjuvant regimens on clinical and pathological response
      rate (in particular relief of dysphagia, improvement in health related quality of life
      (HRQL), endoscopic regression, and CT-PET evidence of tumour response), tumour regression
      grade, node-positivity, post-operative pathology, disease-free survival, time to treatment
      failure, toxicity, post-operative complications and Health Related Quality of Life (HRQL).

      Exploratory Objective(s):

      Translational Research: The collection of blood and tissue samples for storage in the bio
      bank for future research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication:

      Patients with cT2-3 N0-1 M0 adenocarcinoma of the oesophagus or junction, based on clinical,
      CT-PET, and EUS staging, will be randomised to the MAGIC chemotherapy regimen versus the
      CROSS neoadjuvant chemo radiation protocol prior to surgery. Patients will be randomised to
      either Arm A (MAGIC regimen of chemotherapy only and surgery) or Arm B (CROSS protocol:
      chemotherapy with radiation therapy and surgery as per multimodal protocol).

      Eligible patients will be randomised in a 1:1 fashion between the MAGIC regimen or the CROSS
      protocol.

      Exploratory Study- Translational Research :

      Patients enrolled in this trial at the St James's' Hospital site, will be invited to consent
      to having some of their tissue and blood taken for use in future research studies. Following
      consent from the patient, tissue biopsy of tumour and/or normal oesophageal tissue will be
      obtained for research at the same time as that biopsied for histological diagnosis. In
      addition, tumour and/or normal tissue will also be obtained following surgical resection.
      Patient blood samples will also be obtained, both before and during treatment. The
      identification of both tumour and circulating biomarkers will increase knowledge of the
      molecular mechanism(s) underlying treatment response in oesophageal cancer and may facilitate
      the identification of biomarkers predicting patient response to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At end of trial- up to 3 years in follow up</time_frame>
    <description>Overall survival will be calculated from the date of randomisation and an event registered on the date of death from any cause. Patients lost to follow up, or those with no death recorded on the day the database is frozen, will be censored on the date of last follow up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Adenocarcinoma of the Oesophagus</condition>
  <condition>Adenocarcinoma of the Oesophago-gastric Junction</condition>
  <condition>Oesophageal Tumours</condition>
  <condition>Junctional Tumours</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>A (MAGIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAGIC regimen: Arm A consists of 3 cycles of chemotherapy pre-surgery and a further 3 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs used in the MAGIC regimen include Epirubicin, Cisplatin and 5-Flourouracil/ Capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (CROSS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B consists of the CROSS protocol, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive 5 weeks of radiation therapy and 5 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 5 weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive. The chemotherapy and radiotherapy will run concurrently over a 5-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)</description>
    <arm_group_label>A (MAGIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>60mg/m2 on day 1 of each cycle only (i.e. every 21 days).</description>
    <arm_group_label>A (MAGIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 Flourouracil/ Capecitabine</intervention_name>
    <description>5 Flourouracil(200 mg/m2/Day)as a continuous intravenous infusion every day for 21 days/3 weeks, Capecitabine (625 mg/m2 twice daily orally)for 21 days/3 weeks. The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator. 5 Flourouracil/ Capecitabine are given daily for the duration of each cycle (i.e. for 9 weeks pre-surgery and for 9 weeks post-surgery).</description>
    <arm_group_label>A (MAGIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>(41.4 Gy/23 fractions)</intervention_name>
    <description>patient will receive 5 weeks of radiation therapy (41.4 Gy/23 fractions).</description>
    <arm_group_label>B (CROSS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine given IV half an hour before commencing Paclitaxel.Once the Paclitaxel infusion is completed NACL 0.9%,100 ml will be infused IV over half an hour.After this infusion is completed Ondansetron or its equivalent diluted in 100mls NACL 0.9% will be given IV over half an hour on Days 1, 8, 15, 22 and 29.</description>
    <arm_group_label>B (CROSS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose determined as per calculation,infused on Days 1, 8, 15, 22 and 29.</description>
    <arm_group_label>B (CROSS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically verified adenocarcinoma of the oesophagus or oesophago-gastric junction
             based on endoscopy (OGD)

          2. CT-18FDG-PET performed in all patients for disease staging.

          3. EUS in all patients unless luminal obstruction precludes sensitivity of the test.

          4. Staging laparoscopy performed at the investigator's discretion for locally advanced
             AEG II and AEG III tumours .

          5. Pre-treatment stage cT2-3, N0-3, M0.

          6. Maximum tumour length should be no more than 8cm (equal to 8 cm is acceptable)

          7. Male/female patients aged ≥18 years

          8. ECOG Performance Status 0, 1 or 2 (Appendix F).

          9. ASA I-II (Appendix F).

         10. Adequate cardiac function. For all patients, an ejection fraction of &gt; 50% is
             required. If patients have a known cardiac history (e.g. known ischemic disease,
             cardiomyopathy) an ejection fraction &gt; 50% and cardiac clearance by a consultant
             cardiologist for major surgery and cancer therapies is required.

         11. Adequate respiratory function. Patients should have pulmonary function tests completed
             with a minimum FEV1 ≥ 1.5L. CPEX acceptable

         12. Adequate bone marrow function: absolute neutrophil count (ANC) &gt;1.5x109/l; white blood
             cell count &gt;3x109/l; platelets &gt;100x109/l; haemoglobin (Hb) &gt;9g/dl (can be
             post-transfusion).

         13. Adequate renal function: glomerular filtration rate &gt;60ml/minute calculated using the
             Cockcroft-Gault Formula (Appendix O).

         14. Adequate liver function: serum bilirubin &lt;1.5x ULN; AST &lt;2.5x ULN and ALP &lt;3x ULN (ULN
             as per institutional standard).

         15. Written informed consent must be obtained from the patient before any study-trial
             specific procedures are performed.

         16. Women of child-bearing potential and male subjects must agree to use an effective
             barrier method of contraception for up to 6 months following discontinuation of
             therapy. Effective contraception is defined as any medically recommended (or
             combination of methods) as per standard of care.

         17. Women of childbearing potential must have pregnancy excluded by urine or serum
             beta-HCG testing within 7 days prior to treatment.

        Exclusion Criteria:

          1. Tumours of squamous histology.

          2. Patients with advanced inoperable or metastatic oesophageal, junctional or gastric
             adenocarcinoma.

          3. Disease length (total length of tumour plus node) greater than 10cm (up to 10 cm will
             be allowed) -as measured by any modality or, if appropriate, combination of
             modalities-, unless in the opinion of the investigator in discussion with national RT
             lead, it is felt that OAR constraints are likely to be achievable.

          4. Any prior chemotherapy for gastrointestinal cancer.

          5. Prior abdominal or thoracic radiotherapy.

          6. Patients who are unfit for surgery or cancer treatments based on cardiac disease.

          7. Patients with acute systemic infections.

          8. Patients who are receiving treatment with sorivudine or its chemical related
             analogues, such as brivudine which is contraindicated with capecitabine and
             5-fluorouracil administration.

          9. Clinical COPD with significant obstructive airways disease classified by FEV1 &lt; 1.5 L
             or PaO2 less than 9kPa on room air

         10. Known peripheral neuropathy &gt;Grade 1 (absence of deep tendon reflexes as the sole
             neurological abnormality does not render the patient ineligible).

         11. Known positive tests for human immunodeficiency virus (HIV) infection, acute or
             chronic active hepatitis B infection.

         12. Any other malignancies within the last 5 years (other than curatively treated basal
             cell carcinoma of the skin and/or in situ carcinoma of the cervix)

         13. Participation in other clinical trials of investigational or marketed agents for the
             treatment of oesophageal cancer or other diseases within 30 days from registration. UK
             sites please refer to Group Specific Appendix

         14. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V. Reynolds, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trinity Centre, St. James's Hospital, Dublin 8, Ireland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Trials Ireland, Innovation House, Finglas road Dublin 11</last_name>
    <phone>+353 1 6677211</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cancer Trials Ireland</last_name>
    <phone>+353 1 6677211</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Blegdamsvej 9</city>
        <zip>2100 København Ø</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+45 35 45 35 45</phone>
    </contact>
    <investigator>
      <last_name>Dr Lene Baeksgaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional, Universitaire de Lille 2 Avenue Oscar Lambret, 59000</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+33 3 20 44 41 45</phone>
    </contact>
    <investigator>
      <last_name>Prof Guillaume Piessen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust, Northern Ireland Cancer Centre, Belfast CityHospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>contact</last_name>
      <phone>+ 44 028 9097 2756</phone>
    </contact>
    <investigator>
      <last_name>Dr Richard Turkingon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+353 21-4271971</phone>
    </contact>
    <investigator>
      <last_name>Dr Derek Power</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+353 1 809 3000</phone>
    </contact>
    <investigator>
      <last_name>Prof Liam Grogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLRON- St Luke's Radiation Oncology Network</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+353 1 4065000</phone>
    </contact>
    <investigator>
      <last_name>Dr Moya Cunningham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+353 1 410 3000</phone>
    </contact>
    <investigator>
      <last_name>Prof John Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+353 91 524222</phone>
    </contact>
    <investigator>
      <last_name>Dr Greg Leonard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Bournemouth Hospital</name>
      <address>
        <city>The Royal Bournemouth And Christchurch Hospitals NHS Foundation</city>
        <state>Bournemouth</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 1202 726127</phone>
    </contact>
    <investigator>
      <last_name>Joanne Parkinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp</city>
        <state>Cambridge</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 1223 256620</phone>
    </contact>
    <investigator>
      <last_name>Dr Hugo Ford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Velindre NHS Trust, Velindre Road, Whitchurch</city>
        <state>Cardiff</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 29 20 615 888</phone>
    </contact>
    <investigator>
      <last_name>Carys Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Clifford Bridge Road, Walsgrave</city>
        <state>Coventry</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 2476 966 202</phone>
    </contact>
    <investigator>
      <last_name>Sharmila Sothi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Hospital,</name>
      <address>
        <city>Cottingham</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 23 8120 8448</phone>
    </contact>
    <investigator>
      <last_name>Dr Rajarshi Roy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Southwick Hill Road, Cosham</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 2392 286000</phone>
    </contact>
    <investigator>
      <last_name>Freddie Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>E &amp; N Hertfordshire NHS Trust, Rickmansworth Road, Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 203 826 2063</phone>
    </contact>
    <investigator>
      <last_name>Mark Harrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham University Hospitals NHS Trust, Hucknall Road</city>
        <state>Nottingham</state>
        <zip>HG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 115 969 1169</phone>
    </contact>
    <investigator>
      <last_name>Simon Parsons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital NHS Trust Churchill Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 1865 741841</phone>
    </contact>
    <investigator>
      <last_name>Somnath Mukherjee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton General Hospital, Division A Cancer Care, Mp307, T</city>
        <state>Southampton</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 23 8120 8448</phone>
    </contact>
    <investigator>
      <last_name>Dr Andrew Bateman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 1483 571122</phone>
    </contact>
    <investigator>
      <last_name>Shaun Preston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcestershire Oncology Centre, Charles Hastings Way</city>
        <state>Worcester</state>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 1905 733194</phone>
    </contact>
    <investigator>
      <last_name>Mr Martin Wadley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 117 342 0231</phone>
    </contact>
    <investigator>
      <last_name>Dr Stephen Falk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Lothian, Edinburgh Cancer Centre,</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 131 242 3327</phone>
    </contact>
    <investigator>
      <last_name>Dr Sorcha Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 20 3312 6666</phone>
    </contact>
    <investigator>
      <last_name>Prof George Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospital NHS Foundation TrustFreeman Hospital, Freeman Road, High Heaton</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>+44 191 233 6161</phone>
    </contact>
    <investigator>
      <last_name>Prof Michael Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

